SCHEMBL4616633

SCHEMBL4616633

Cc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)NCc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SFRP1 Q8N474 1/20 0.76
CA12 O43570 2/20 0.60
CA9 Q16790 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
ATM Q13315 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KEAP1 Q14145 1/20 0.59
LMNA P02545 1/20 0.58
SLC12A2 P55011 1/20 0.58
SLC12A5 Q9H2X9 1/20 0.58
BRD4 O60885 1/20 0.57
BRD2 P25440 1/20 0.57
BRD3 Q15059 1/20 0.57
GLA P06280 1/20 0.56
POLB P06746 2/20 0.54
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 1/20 0.52
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616070 0.92 SFRP1 (0.66) SFRP1CA12CA9CYP1A2CYP3A4
SCHEMBL4619139 0.89 ALDH1A1 (0.64) SFRP1CYP1A2LMNAALDH1A1SMN1; SMN2
SCHEMBL4616099 0.86 SFRP1 (1.00) SFRP1L3MBTL1BRD4BRD2BRD3
SCHEMBL4616503 0.84 SFRP1 (0.86) SFRP1BRD4BRD2BRD3POLB
SCHEMBL4619292 0.83 SFRP1 (0.68) SFRP1L3MBTL1LMNAPOLBALDH1A1
SCHEMBL4618631 0.83 SFRP1 (0.76) SFRP1CA12CA9L3MBTL1LMNA
SCHEMBL4616903 0.82 SFRP1 (0.90) SFRP1L3MBTL1BRD4BRD2BRD3
SCHEMBL4617781 0.81 SFRP1 (0.61) SFRP1L3MBTL1LMNABRD4BRD2
SCHEMBL4617492 0.81 SFRP1 (0.65) SFRP1CA12CA9L3MBTL1LMNA
SCHEMBL19400889 0.81 NPC1 (0.73) CA12CA9CYP1A2CYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 SFRP1 1/4885CA12 1740/4885CA9 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.